CRISPR-Cas9 is widely used to edit the genome by studying genes of interest and modifying disease-associated genes. However, this process is associated with side effects including unwanted mutations and toxicity. Therefore, a new technology that reduces these side effects is needed to improve its usefulness in industry and medicine. Now, researchers at Kyushu University in […]
DISEASE OVERVIEW Fibrodysplasia ossificans progressiva (FOP) is an extremely rare genetic connective tissue disorder characterized by the abnormal development of bone in areas of the body where bone is not normally present (heterotopic ossification), such as the ligaments, tendons and skeletal muscles. Specifically, this disorder causes the body’s skeletal muscles and soft connective tissues to […]
The Fibrodysplasia Ossificans Progressiva Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the […]
Purpose of the study Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant condition that leads to significant disability and morbidity, characterised by the formation of heterotopic hard tissues within connective tissues. The condition has an incidence of approximately one per two million people worldwide. There is no known single effective treatment available for FOP. […]
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder of extraskeletal endochondral bone formation. Heterozygous missense gain-of-function mutations in the activin receptor A type I (ACVR1) gene are present in all individuals with sporadic or familial FOP. ACVR1R206H mutations confer increased sensitivity of this bone morphogenetic protein (BMP) family receptor to activation by BMP ligands and […]
1. Introduction Fibrodysplasia ossificans progressiva (FOP) is a rare but devastating autosomal dominant genetic disorder characterized by spontaneous or trauma-induced progressive extra-skeletal bone formation, called heterotopic ossification (HO), in skeletal muscles, tendons, and ligaments [1]. HO forms through endochondral ossification, the process that creates most bones during embryonic development [2]. Endochondral ossification occurs through the […]
Abstract Introduction and importance Fibrodysplasia Ossificans Progressiva is an ultra-rare genetic disorder of progressive soft tissue ossification. Due to unawareness and poor clinical suspicion, the rate of misdiagnosis, delay in diagnosis, and unnecessary diagnostic procedures leading to permanent injury and lifelong disability is common. Here we report this rare genetic disorder in a six years […]
Introduction Fibrodysplasia ossificans progressiva (FOP) is a rare, progressively debilitating disorder first described in 1692 by Guy Patin [1]. This disease is characterized by progressive heterotopic ossification that forms normal bone in characteristic extraskeletal sites and congenital malformations of the great toes. Progressive episodes of heterotopic ossification occur in characteristic pattern first at the dorsal, axial, […]
Precious Chiamaka na six-year-old wen her mama bin notice say one small bone dey grow for di back of her hand. As she no sabi wetin dey grow for di back of her pikin hand, Precious mama carry her go hospital and na for dia dem come tell her say na her muscles dey turn […]
Fibrodysplasia ossificans progressiva is a rare and life-threatening genetic disease caused by gain-of-function mutations in the ALK2 gene, which encodes activin receptor-like kinase 2. Blueprint Medicines Corp. has elucidated the discovery of their ALK2 inhibitor BLU-782, which is now in phase II studies at Ipsen for the treatment of FOP. Source: Bio World
